<- Go Home
Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Market Cap
$577.7M
Volume
3.9M
Cash and Equivalents
$63.0M
EBITDA
-$98.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$66.7M
Profit Margin
215138.71%
52 Week High
$6.44
52 Week Low
$2.56
Dividend
N/A
Price / Book Value
1.22
Price / Earnings
-4.09
Price / Tangible Book Value
1.22
Enterprise Value
$287.5M
Enterprise Value / EBITDA
-2.93
Operating Income
-$98.7M
Return on Equity
28.87%
Return on Assets
-17.20
Cash and Short Term Investments
$326.3M
Debt
$36.0M
Equity
$474.2M
Revenue
$31.0K
Unlevered FCF
-$46.6M
Sector
Biotechnology
Category
N/A